James R. Berenson, MD, Inc.

Dr. James Berenson discusses the importance of using maintenance therapies with limited short- or long-term side effects, in particular avoiding therapies that have long-term toxicity. Dr. Berenson expresses his excitement that within the next few years there is hope for curative therapy by using drugs that are “piggybacked” and delivered at a “thousand folds” higher […]

New drugs provide powerful options, but little consensus on standard treatments New York—There is a profound disagreement over whether early stem cell transplant (SCT) should still be characterized as a standard early intervention for multiple myeloma (MM), even in relatively young patients. Newer drugs are yielding response rates comparable to transplant, and this development has […]

Posted By Navneet Ramesh and Maike Haehle  on the Myeloma Beacon on Aug 31, 2013 2:01 Researchers recently reported updated sur­viv­al rates for multiple mye­lo­ma patients in the United States.  The results show that sur­viv­al has im­proved steadily – and markedly – from 1998 to 2009. The average newly diagnosed myeloma patient 15 years ago, for exam­ple, was about one-third […]